These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

786 related items for PubMed ID: 18055183

  • 1. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
    Adembri C, Fallani S, Cassetta MI, Arrigucci S, Ottaviano A, Pecile P, Mazzei T, De Gaudio R, Novelli A.
    Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
    [Abstract] [Full Text] [Related]

  • 2. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients.
    Rafati MR, Rouini MR, Mojtahedzadeh M, Najafi A, Tavakoli H, Gholami K, Fazeli MR.
    Int J Antimicrob Agents; 2006 Aug; 28(2):122-7. PubMed ID: 16815689
    [Abstract] [Full Text] [Related]

  • 3. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients.
    Dong H, Wang X, Dong Y, Lei J, Li H, You H, Wang M, Xing J, Sun J, Zhu H.
    Int J Antimicrob Agents; 2011 Oct; 38(4):296-300. PubMed ID: 21741222
    [Abstract] [Full Text] [Related]

  • 4. Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia.
    Boselli E, Breilh D, Caillault-Sergent A, Djabarouti S, Guillaume C, Xuereb F, Bouvet L, Rimmelé T, Saux MC, Allaouchiche B.
    J Antimicrob Chemother; 2012 May; 67(5):1207-10. PubMed ID: 22351682
    [Abstract] [Full Text] [Related]

  • 5. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J.
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis.
    Stein GE, Schooley SL, Peloquin CA, Kak V, Havlichek DH, Citron DM, Tyrrell KL, Goldstein EJ.
    Ann Pharmacother; 2005 Mar; 39(3):427-32. PubMed ID: 15701775
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections.
    MacGowan AP.
    J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii17-25. PubMed ID: 12730139
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Plasma exposure of free linezolid and its ratio to minimum inhibitory concentration varies in critically ill patients.
    Yagi T, Naito T, Doi M, Nagura O, Yamada T, Maekawa M, Sato S, Kawakami J.
    Int J Antimicrob Agents; 2013 Oct; 42(4):329-34. PubMed ID: 23988716
    [Abstract] [Full Text] [Related]

  • 11. Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration.
    De Pascale G, Fortuna S, Tumbarello M, Cutuli SL, Vallecoccia M, Spanu T, Bello G, Montini L, Pennisi MA, Navarra P, Antonelli M.
    Intensive Care Med; 2015 Jan; 41(1):103-10. PubMed ID: 25413377
    [Abstract] [Full Text] [Related]

  • 12. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
    Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J.
    J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill.
    Whitehouse T, Cepeda JA, Shulman R, Aarons L, Nalda-Molina R, Tobin C, MacGowan A, Shaw S, Kibbler C, Singer M, Wilson AP.
    J Antimicrob Chemother; 2005 Mar; 55(3):333-40. PubMed ID: 15705641
    [Abstract] [Full Text] [Related]

  • 14. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
    Dong H, Xie J, Chen L, Wang T, Sun J, Zhao Y, Dong Y.
    Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of free ertapenem in critically ill septic patients: intermittent versus continuous infusion.
    Breilh D, Fleureau C, Gordien JB, Joanes-Boyau O, Texier-Maugein J, Rapaport S, Boselli E, Janvier G, Saux MC.
    Minerva Anestesiol; 2011 Nov; 77(11):1058-62. PubMed ID: 21597443
    [Abstract] [Full Text] [Related]

  • 16. [Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia].
    Cousson J, Floch T, Vernet-Garnier V, Appriou M, Petit JS, Jovenin N, Lamiable D, Hoizey G.
    Pathol Biol (Paris); 2005 Nov; 53(8-9):546-50. PubMed ID: 16023303
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.
    Burgess DS, Summers KK, Hardin TC.
    Clin Ther; 1999 Nov; 21(11):1882-9. PubMed ID: 10890260
    [Abstract] [Full Text] [Related]

  • 18. Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation.
    Fiaccadori E, Maggiore U, Rotelli C, Giacosa R, Parenti E, Picetti E, Manini P, Andreoli R, Cabassi A.
    Nephrol Dial Transplant; 2006 May; 21(5):1402-6. PubMed ID: 16504979
    [Abstract] [Full Text] [Related]

  • 19. In vitro analysis of resistance selection by linezolid in vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium.
    Allen GP, Bierman BC.
    Int J Antimicrob Agents; 2009 Jul; 34(1):21-4. PubMed ID: 19243921
    [Abstract] [Full Text] [Related]

  • 20. Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia.
    Jaruratanasirikul S, Sriwiriyajan S, Ingviya N.
    J Pharm Pharmacol; 2002 Dec; 54(12):1693-6. PubMed ID: 12542901
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.